Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy

Journal of Neurosurgery

Volumn 103, Issue 6, 2005, Pages 1058-1066

  Wang, Weijun ^b   Zhu, Nian Ling ^b   Chua, Jason ^b   Swenson, Steve ^b   Costa, Fritz K ^b   Schmitmeier, Stephanie ^b   Sosnowski, Barbara A ^b   Shichinohe, Toshiaki ^b   Kasahara, Noriyuki ^b   Chen, Thomas C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

Adenoviral vector; Basic fibroblast growth factor; Gene transfer; Malignant glioma; Mouse

Indexed keywords

ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GREEN FLUORESCENT PROTEIN; INTEGRIN ALPHA 5 BETA 5; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; GENE ACTIVITY; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

EID: 32044446998     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2005.103.6.1058     Document Type: Article

References (44)

1. Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H: Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 92:1002-1008, 2000
2. Bai M, Campisi L, Freimuth P: Vitronectin receptor antibodies inhibit infection of HeLa and A549 cells by adenovirus type 12 but not by adenovirus type 2. J Virol 68:5925-5932, 1994
3. Bai M, Harfe B, Freimuth P: Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol 67:5198-5205, 1993
4. Belin MT, Boulanger P: Involvement of cellular adhesion sequences in the attachment of adenovirus to the HeLa cell surface. J Gen Virol 74:1485-1497, 1993
5. Berens ME, Rutka JT, Rosenblum ML: Brain tumor epidemiology, growth, and invasion. Neurosurg Clin N Am 1:1-18, 1990
6. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323, 1997
7. Bilbao G, Feng M, Rancourt C, Jackson WH Jr, Curiel DT: Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 11:624-634, 1997
8. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571, 1994
9. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, et al: A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10:958-966, 2004
10. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14:1574-1578, 1996
11. Doukas J, Hoganson DK, Ong M, Ying W, Lacey DL, Baird A, et al: Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB J 13:1459-1466, 1999
12. Freimuth P: A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor. J Virol 70:4081-4085, 1996
13. Fuxe J, Liu L, Malin S, Philipson L, Collins VP, Pettersson RF: Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer 103:723-729, 2003
14. Giles GG, Gonzales MF: Epidemiology of brain tumors and factors in prognosis, in Kay AH, Laws ER Jr (eds): Brain Tumors. An Encyclopedic Approach, ed 2. London: Churchill Livingstone, 2001, pp 51-70
15. Gladson CL, Cheresh DA: Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 88:1924-1932, 1991
16. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA: Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci 108:947-956, 1995
17. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, et al: Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 57:1447-1451, 1997
18. Gu DL, Gonzalez AM, Printz MA, Doukas J, Ying W, D'Andrea M, et al: Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res 59:2608-2614, 1999
19. Hoganson DK, Sosnowski BA, Pierce GF, Doukas J: Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol Ther 3:105-112, 2001
20. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, et al: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10:967-972, 2004
21. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT: Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 70:6839-6846, 1996
22. Lowenstein PR: Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol 23:23-30, 2002
23. Mittereder N, March KL, Trapnell BC: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70:7498-7509, 1996
24. Morrison RS, Gross JL, Herblin WF, Reilly TM, LaSala PA, Alterman RL, et al: Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line. Cancer Res 50:2524-2529, 1990
25. Morrison RS, Yamaguchi F, Saya H, Bruner JM, Yahanda AM, Donehower LA, et al: Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol 18:207-216, 1994
26. Pileri SA, Roncador G, Ceccarelli C, Piccioli M, Briskomatis A, Sabattini E, et al: Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol 183:116-123, 1997
27. Printz MA, Gonzalez AM, Cunningham M, Gu DL, Ong M, Pierce GF, et al: Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther 11:191-204, 2000
28. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, et al: Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 9:1769-1774, 1998
29. Rainov NG: A phase III clinical evaluation of herpes simplex virus type I thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401, 2000
30. Reynolds PN, Miller CR, Goldman CK, Doukas J, Sosnowski BA, Rogers BE, et al: Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells. Tumor Targeting 3:156-168, 1998
31. Ruoslahti E: Integrins. J Clin Invest 87:1-5, 1991
32. Shenk T: Adenoviridae: the viruses and their replication, in Fields BN, Knipe DM, Howley PM (eds): Fundamental Virology, ed 3. Philadelphia: Lippincott-Raven, 1996, pp 979-1016
33. Sosnowski BA, Gu DL, D'Andrea M, Doukas J, Pierce GF: FGF2-targeted adenoviral vectors for systemic and local disease. Curr Opin Mol Ther 1:573-579, 1999
34. Stevenson SC, Rollence M, Marshall-Neff J, McClelland A: Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 71:4782-4790, 1997
35. Swenson S, Costa F, Minea R, Sherwin RP, Ernst W, Fujii G, et al: Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 3:499-511, 2004
36. Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M: Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76:792-798, 1992
37. Tomko RP, Xu R, Philipson L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and Group B coxsackieviruses. Proc Natl Acad Sci U S A 94:3352-3356, 1997
38. Ueba T, Takahashi JA, Fukumoto M, Ohta M, Ito N, Oda Y, et al: Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. Neurosurgery 34:221-226, 1994
39. Wickham TJ: Targeting adenovirus. Gene Ther 7:110-114, 2000
40. Wickham TJ, Carrion ME, Kovesdi I: Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 2:750-756, 1995
41. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319, 1993
42. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG: Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8:37-44, 1997
43. Yoshida Y, Sadata A, Zhang W, Saito K, Shinoura N, Hamada H: Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum Gene Ther 9:2503-2515, 1998
44. Zhu N, Sosnowski BA, Zlokovic BV, Ong M, Chen TC: Targeted cytotoxic gene delivery to malignant gliomas via the fibroblast growth factor receptor. Neurosurg Focus 8(4):E4, 2000